The Tolerability of in the Adjuvant Treatment of Breast Cancer Comprising Sequential Anthracycline and Taxane Treatment: Single Center Experience
| Autor: | Efnan Algin, Umut Demirci, Ugur Coskun, Ayşe Demirci, Fatma Buğdaycı Başal, Deniz Yamaç, Hacer Demir |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Gynecology
medicine.medical_specialty business.industry General Medicine Stage ii Neutropenia medicine.disease antracycline dose dense therapy breast cancer taxan advers events chemistry.chemical_compound Breast cancer Quality of life Docetaxel Paclitaxel chemistry antrasiklin doz yoğun tedavi meme kanseri taksan yan etki Adjuvant therapy Medicine Stage (cooking) business medicine.drug |
| Zdroj: | Volume: 47, Issue: 2 8-15 Acta Oncologica Turcica |
| ISSN: | 0304-596X 2148-7669 |
| Popis: | OBJECTIVE: We studied the side effects associated with the adjuvant therapy combinations containing anthracycline-taxane which is the most frequently used recently in the breast cancer. Our goal is to demonstrate these side effects affecting patient quality of life and treatment success and to emphasize the importance of patient awareness.METHODS: In the study, the files of one hundred patients with diagnosis of breast cancer were investigated retrospectively.RESULTS: Sixty of the patients (60%) were premenopausal and 40 of them (40%) were postmenopausal (40%). One (%1) patient was stage I, 52 (52%) patients were stage II, 47 (47%) patients were stage III. While 31 of the patients received intensive therapy [paclitaxel (n=26, 80.7%), docetaxel (n=5,19.3%)], 69 of them received 3 weekly therapy [paclitaxel (n=10, 14.4%), docetaxel (n=59, 85.6%)]. Neuropathy, neutropenia and nail changes were found to be more frequent (32.3%, p AMAÇ: Bu çalışmada adjuvan kemoterapi olarak ardışık antrasiklin ve taksan içeren kombinasyonları alan meme kanserli hastalarda gelişen yan etkileri inceledik. Amacımız hasta yaşam kalitesini ve tedavi başarısını etkileyen bu yan etkilerin ortaya konması ve hasta bilgilendirmesinin öneminin vurgulanmasıdır.YÖNTEMLER: Çalışmamızda tek merkezde takipli opere meme kanserli 100 hastanın dosyaları retrospektif olarak incelendi.BULGULAR: Altmışı (%60) premenopozal 100 hastanın ortanca yaşı 47,6 (aralık; 20-74) idi. Bir (%1) hasta evre I, 52 (%52) hasta evre II, 47 (%47) hasta evre III idi. Hastaların 31'i doz yoğun tedavi (DYT) [paklitaksel (n=26, %80.7), dosetaksel (n=5, %19.3)], 69'u 3 haftalık tedavi [paklitaksel (n=10, %14.4), dosetaksel (n=59, %85.6)] almıştı. DYT rejimleri ile daha sık nöropati (%32.3, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|